Navigation Links
Warner Chilcott Announces $500 Million Senior Notes Offering in Connection With Agreement to Acquire U.S. Rights to Enablex®

Warner Chilcott Announces $500 Million Senior Notes Offering in Connection With Agreement to... -- ARDEE, Ireland, Sept. 24 /PRNewswire-FirstCall/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Banking & Financial Services, Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Stock Offering Click to view news release full screen  

Warner Chilcott Announces $500 Million Senior Notes Offering in Connection With Agreement to Acquire U.S. Rights to Enablex®


ARDEE, Ireland, Sept. 24 /PRNewswire-FirstCall/ -- Warner Chilcott plc (Nasdaq: WCRX) today announced that its subsidiaries, Warner Chilcott Company, LLC and Warner Chilcott Finance LLC (together, the "Issuers"), plan to issue an aggregate principal amount of $500 million of 7-3/4% senior notes due 2018 (the "Notes") in a private placement.  The notes are additional notes constituting a part of the same series as the $750 million aggregate principal amount of 7-3/4% senior notes due 2018 issued on August 20, 2010.

The Issuers' obligations under the Notes will be guaranteed by Warner Chilcott plc and by its subsidiaries that guarantee obligations under Warner Chilcott's senior secured credit facilities, subject to certain exceptions.

Warner Chilcott intends to use the net proceeds from the offering to finance its $400 million upfront payment in connection with its pending acquisition of the U.S. rights to Enablex® from Novartis and for general corporate purposes.  

The Notes have not been registered under the Securities Act of 1933, as amended.  The Notes may not be offered or sold within the United States or to U.S. persons, except to "qualified institutional buyers" in reliance on the exemption from registration provided by Rule 144A and to certain persons in offshore transactions in reliance on Regulation S.  This announcement does not constitute an offer to sell or the solicitation of an offer to buy Notes in any jurisdiction in which such an offer or sale would be unlawful.

About Warner ChilcottWarner Chilcott is a leading specialty pharmaceutical company currently focused on the gastroenterology, women's healthcare, dermatology and urology segments of the North American and Western European pharmaceuticals markets. The Company is fully integrated with internal resources dedicated to the development, manufacturing and promotion of its products. WCRX-F.

Forward Looking StatementsThis press release contains forward-looking statements, including statements concerning the incurrence of new debt, as well as concerning our operations, our anticipated financial performance and financial condition, and our business plans and growth strategy and product development efforts. These statements constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words "may," "might," "will," "should," "estimate," "project," "plan," "anticipate," "expect," "intend," "outlook," "believe" and other similar expressions are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties. The following represent some, but not necessarily all, of the factors that could cause actual results to differ from historical results or those anticipated or predicted by our forward-looking statements: our substantial indebtedness, including increases in the LIBOR rates on our variable-rate indebtedness above the applicable floor amounts; competitive factors in the industry in which we operate (including the approval and introduction of generic or branded products that compete with our products); our ability to protect our intellectual property; a delay in qualifying our manufacturing facilities that produce our products or production or regulatory problems with either third party manufacturers or API suppliers upon whom we may rely for some of our products or our own manufacturing facilities; pricing pressures from reimbursement policies of private managed care organizations and other third party payors, government sponsored health systems, the continued consolidation of the distribution network through which we sell our products, including wholesale drug distributors and the growth of large retail drug store chains; the loss of key senior management or scientific staff; adverse outcomes in our outstanding litigation or an increase in the number of litigation matters to which we are subject; government regulation, including domestic and foreign health care reform, affecting the development, manufacture, marketing and sale of pharmaceutical products, including our ability and the ability of companies with whom we do business to obtain necessary regulatory approvals; our ability to manage the growth of our business by successfully identifying, developing, acquiring or licensing new products at favorable prices and marketing such new products; our ability to obtain regulatory approval and customer acceptance of new products, and continued customer acceptance of our existing products; changes in tax laws or interpretations that could increase our consolidated tax liabilities; our ability to realize the anticipated opportunities from our acquisition of the global branded pharmaceuticals business from The Procter and Gamble Company; the other risks identified in our periodic filings including our Annual Report on Form 10-K for the year ended December 31, 2009 and from time-to-time in our other investor communications.

We caution you that the foregoing list of important factors is not exclusive. In addition, in light of these risks and uncertainties, the matters referred to in our forward-looking statements may not occur. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as may be required by law.


SOURCE Warner Chilcott plc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Warner Chilcott to Present at UBS Global Life Sciences Conference
2. Warner Chilcott Announces Receipt of FDA Response to Citizen Petition
3. Warner Chilcott Completes Amendment to Existing Senior Secured Credit Facilities and Closes Senior Notes Offering; Company Declares Special Cash Dividend of $8.50 Per Share and Updates Full-Year 2010 Financial Guidance
4. Warner Chilcott Announces Earnings Release Date and Conference Call for Second Quarter 2010 Financial Results
5. Warner Chilcott Announces 3-Month Extension of PDUFA Date on Next Generation Actonel Product
6. Warner Chilcott Announces Receipt of Paragraph IV Certification Notice
7. Warner Chilcott to Present at the Wells Fargo Securities Healthcare Conference
8. Warner Chilcott to Present at the Bank of America Merrill Lynch Healthcare Conference
9. Warner Chilcott Announces Earnings Release Date and Conference Call For First Quarter 2010 Financial Results
10. Warner Chilcott Announces 2010 Financial Guidance Conference Call
11. Warner Chilcott Announces Early Tender Results and Receipt of Consents from a Majority of Holders of its 8-3/4% Senior Subordinated Notes due 2015
Post Your Comments:
(Date:10/13/2015)... 2015 Health Gorilla ( ) today announced ... – a secure platform for clinical data and communications poised ... and manage healthcare in the US. The launch follows the ... combined total of $4.4M raised to date, with Data ... Ventures , Harris Barton , Orfin Ventures ...
(Date:10/13/2015)... , October 13, 2015 --> ... ,What can be expected from the Asthma and COPD Therapies ... rates? Visiongain ,s brand new report shows you potential ... ,  ,Our 309-page report provides 260 tables, charts, and graphs. ... future market prospects. Our new study lets you assess forecasted ...
(Date:10/13/2015)... SPRINGS, N.C. , Oct. 13, 2015  Yesterday ... NVS Influenza Vaccines Holly Springs manufacturing site located in ... Since 2014, the facility has produced Flucelvax ® ... has the potential for faster start-up and is not ... 2015 CSL Limited acquired the influenza vaccines business of ...
Breaking Medicine Technology:
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... "My friend's ... his fists into his infected cheeks," said an inventor from Platteville, Colo. "I came ... skin problems." , He developed the UNTOUCHABLE to prevent a child from rubbing or ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... of anesthesia and pain management services, today announced its partnership with WPC ... integrates data from disparate systems and organizes the data into an aggregated data ...
(Date:10/13/2015)... ... ... According to an article published October 5th by the American ... weight with a bariatric procedure are much less likely to develop endometrial cancer, which ... from 40 to 50 percent of all endometrial cancer cases are caused by obesity, ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... solutions, announced today their sponsorship of the Microsoft Dynamics AXUG, GPUG and NAVUG ... Summit, GPUG Summit and NAVUG Summit are independent user conferences designed and led ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... provider of IBM software products, introduced a new company, RightSensor™ LLC, an Internet ... data communications capability. RightSensor™ provides a fully-managed approach for customers requiring sensor ...
Breaking Medicine News(10 mins):